GATA3 EMSA Kit
- Known as:
- GATA3 EMSA Kit
- Catalog number:
- AY1096
- Product Quantity:
- 25 rxn
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- GATA3 EMSA Kit
Related genes to: GATA3 EMSA Kit
- Gene:
- GATA3 NIH gene
- Name:
- GATA binding protein 3
- Previous symbol:
- -
- Synonyms:
- HDR
- Chromosome:
- 10p14
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2016-10-05
Related products to: GATA3 EMSA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: GATA3 EMSA Kit
- Multiple pools of developmental progenitors are needed for kidney regeneration, but directing differentiation of each of these independently is rate limiting and disruptive to the process. We demonstrate that a mere 4 days of differentiation generates an induced metanephric mesenchyme (iMM) containing both nephron progenitor cells and renal stromal progenitor cells. When implanted beneath the kidney capsule of immunodeficient mice, iMM differentiates into podocytes, mesangial cells, and tubules that recruit host blood vessels to form glomeruli and peritubular capillaries. In contrast, mature organoids rapidly lose differentiated features after implantation and fail to become productively vascularized by the host. By examining morphological changes and gene expression patterns, we demarcate a window of opportunity for successful implantation during which iMM exists . Young organoid cultures containing epithelial and stromal progenitor cells thus provide a rapid, one-pot starting material for nephron regeneration, a concept that may be broadly applicable to many organ systems. - Source: PubMed
Publication date: 2026/01/29
Vincent ThomasNademi SameraNamestnikov MichaelCohen-Zontag OsnatDekel BenjaminFreedman Benjamin S - Molecular subtyping is critical for prognostic stratification and treatment in bladder cancer (BCa). However, few studies have combined immunohistochemistry (IHC)-based subtyping with spatial immune profiling and predictive biomarker evaluation. In this study, we retrospectively analyzed 109 BCa patients using a three-part profiling strategy: (1) molecular classification into basal, luminal, double-positive (DP), and double-negative (DN) subtypes with basal (CK5/6, CD44) and luminal (CK20, GATA3) markers, merging DP tumors with basal for analysis; (2) assessment of tumor biology by evaluating p53, PTEN, PD-L1, and mismatch repair (MMR) proteins; (3) multiplex IHC and digital pathology-assisted spatial quantification of immune cells. Basal-subtype tumors showed frequent PTEN loss (P = 0.032) and a novel nuclear PD-L1 pattern (P = 0.043) linked to chemoresistance and recurrence (P = 0.049). MMR profiling revealed reduced PMS2 expression (P < 0.0001) and coordinated downregulation of MMR proteins in PTEN-low tumors. Immune analysis indicated an immune-hot phenotype, but nuclear PD-L1 positivity did not correlate with T-cell density. This study highlights the significance of PTEN loss and nuclear PD-L1 expression in basal subtype BCa, contributing to improved risk stratification and potential precision treatments in bladder cancer. - Source: PubMed
Publication date: 2026/05/02
Zheng QiaoliZhao TingLiao EnyiCao ZhixingWang Shuang - Type 2 high asthma is driven by coordinated GATA3 dependent programs in CD4 T cells and group 2 innate lymphoid cells (ILC2). Although biologics targeting IL4, IL5, or IL13 benefit subsets of patients, many remain symptomatic, suggesting that upstream regulatory mechanisms may sustain type 2 inflammation. We investigated whether HuR (ELAVL1), an RNA-binding protein that stabilizes GATA3 and Th2 cytokines mRNA, regulates type 2 inflammatory programs in allergic asthma. Using a house dust mite (HDM) model in vivo, HuR inhibition with the small molecule KH3 reduced lung inflammation, suppressed Th2 cytokine expression, accelerated Gata3 mRNA decay in lung CD4 T cells, and attenuated airway hyperresponsiveness toward control levels. In ex vivo activated human lung CD4 T cells, KH3 accelerated GATA3 mRNA decay with minimal effects on RORC or TBX21 and selectively reduced Th2 cytokine secretion, while IL10 and IL2 were unchanged. Similarly, ILC2s isolated from peripheral blood mononuclear cells (PBMCs) of type 2 high asthmatic donors showed reduced GATA3 mRNA stability and diminished Th2 cytokine production following KH3 treatment. Single-cell transcriptomic analysis of bronchoalveolar lavage fluid after allergen challenge demonstrated co-enrichment of ELAVL1 and GATA3 within Th2 clusters in human airways. Together, these findings identify HuR as a post-transcriptional regulator of GATA3 driven type 2 inflammation in allergic asthma. - Source: PubMed
Publication date: 2026/04/27
Atasoy UlusFattahi FatemehYaekle LauraHolden JuliaTepper BrandonHussein KareemMeier JoshuaXu LiangNerella SrilaxmiLei JingBentley KelleyHershenson MarcHuang Steven K - Mouse mammary epithelial cells possess a remarkable ability to regenerate the entire mammary gland through precisely regulated differentiation, involving complex molecular, morphological, and functional changes. Here, we performed comprehensive transcriptomic profiling of HC11 mouse mammary epithelial cells undergoing lactogenic differentiation using RNA sequencing and integrative bioinformatics. We identified 566 differentially expressed genes, reflecting extensive transcriptional reprogramming and activation of biosynthetic, metabolic, and secretory programs. Strong up-regulation of terminal and lactogenic differentiation markers, including Wap, Csn2, Lpl, Cd36, Lalba, Btn1a1, Xdh, Gata3, and Cebpb, signified maturation into a secretory phenotype. Functional evaluation via gene set enrichment analysis revealed transcriptional enrichment of mTOR, prolactin, insulin, ErbB, and autophagy-associated pathways, consistent with anabolic readiness and terminal differentiation. Conversely, p53, Wnt, and FoxO pathways were down-regulated, marking a transition from proliferation to differentiation. Transcription factors (FoxO1, Zbtb16, and Srebf1) and epigenetic regulators (Gadd45a and Hist1h1e) exhibited dynamic changes, underscoring coordinated transcriptional and chromatin remodeling. Gene set enrichment and protein-protein interaction analyses identified 10 hub genes, Agt, Ccnd1, Igf1, Mki67, Myc, Calm4, Rasgrp1, Cd69, Il6, and Pecam1, as central drivers of differentiation. Clustering of uniquely regulated genes further implicated roles in milk synthesis, protease activity, and lineage stabilization. Together, these findings define a transcriptional framework for lactogenic differentiation in the HC11 cell line model and provide a basis for future mechanistic studies. - Source: PubMed
Publication date: 2026/05/04
Ahmad WaqarPanicker Neena GopinathanRizvi Tahir AMustafa Farah - Somatic mutations in protein-coding genes and noncoding regulatory regions are the major drivers of cancer. Only a relatively small number of somatic noncoding mutations that are likely drivers have been described to date, including those in the promoters of the , and genes. The impact of these alterations can be profound by initiating, increasing, or abolishing gene expression. Promoter mutations in particular have been difficult to identify even from whole tumor genomes due to their high content of G and C nucleotides, which leads to loss of sequencing coverage in these regions. Therefore, the landscape of somatic drivers in gene promoters remains incomplete. Here, we present a hybrid capture assay optimized for >3000 promoters of cancer genes. We show that this assay allows for deep sequencing of challenging GC-rich promoter regions, enabling discovery of reliable point mutations, short insertions and deletions, copy number variants, and mutational signatures in cell line models as well as formalin-fixed, paraffin-embedded archival tissue samples. Our assay nominated candidate noncoding driver mutations in , and in breast cancer for future functional follow-up. - Source: PubMed
Publication date: 2026/05/04
Qi MeifangDave Preshita SanjayFrancis NicoleDeFelice MatthewPollock SamCorbitt HollyMitsiades Irene RinWang GengchaoFrere PaulFox AlanKhitrov GregoryPetersen CarolineLarkin KatieHamilton SusannaEllisen Leif WGulhan Doga CHidalgo-Miranda AlfredoLennon NiallCibulskis CarrieRheinbay Esther